详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer.

98| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

出处：

DOI：

ISSN：

关键词： immune checkpoint inhibitor Kirsten rat sarcoma inhibitor Kirsten rat sarcoma mutation nonsmall cell lung cancer

摘要：

The unique structure made Kirsten rat sarcoma (KRAS) 'undruggable' for quite an extended period. The functional mechanism of this small protein is well illustrated. However, there is no precision medicine for nonsmall cell lung cancer (NSCLC) patients burden with KRAS mutation. The attempts made by scientists to make challenge history against KRAS mutation and their druggable targets are worth elucidating.The appearance of orphan drug AMG510 in the market specifically targeting KRASG12C is a tremendous breakthrough. Several KRAS inhibitors are under development now. More studies focus on combo treatment of KRAS inhibition and immune checkpoint inhibitors (ICIs). Recent preclinical and clinical investigations have been reported that NSCLC patients with KRAS mutation can benefit from ICIs.The current review elucidates the development of KRAS inhibitors from basic research to clinical precision medicines. We retrospectively analyze the development of KRAS mutation targeting drugs and discuss the investigations for future development of KRAS inhibitors.Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版中科院分区表Review为是的期刊

：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2023]版

：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2022]版：

Q3 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 2.8 最新[2023版] 3.1 最新五年平均 3.4 出版当年[2022版] 3.4 出版当年五年平均 3.915 出版前一年[2021版] 2.8 出版后一年[2023版]

第一作者：

第一作者机构： [1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

共同第一作者：

通讯作者：

通讯机构： [1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [*1]Integrative Cancer Center and Cancer Clinical Research Center, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer.

文献详情

相关文献